The GLP-1 and cancer debate is increasingly being discussed not only as a safety question, but also as a prevention and pharmacovigilance question. Recent academic studies are examining whether glucagon-like peptide-1 receptor agonists are associated with cancer risk among adults with obesity or type 2 diabetes. The question is clinically important because GLP-1 receptor agonists are widely prescribed for glycemic control in type 2 diabetes and have gained popularity for weight management, while their long-term impact on cancer risk remains uncertain. 1
Obesity, Type 2 Diabetes, and Obesity-Associated Cancers
The relevance to oncology comes from the risk profile of the treated populations. Overweight and obesity are associated with a higher risk of 13 cancer types, and these cancers account for approximately 40% of all cancers diagnosed annually in the United States. 2
The U.S. Centers for Disease Control and Prevention lists these 13 obesity-associated cancers as adenocarcinoma of the esophagus, postmenopausal breast cancer, colorectal cancer, uterine cancer, gallbladder cancer, upper stomach cancer, kidney cancer, liver cancer, ovarian cancer, pancreatic cancer, thyroid cancer, meningioma, and multiple myeloma. 2
Against this background, the central question is not whether GLP-1 receptor agonists are oncology drugs. These agents are not approved as oncology treatments or cancer-prevention drugs. The more precise question is whether medicines used for glycemic control and weight management could influence cancer incidence in populations already at elevated risk for obesity-associated cancers. Current evidence supports investigation of this question, but it does not justify describing GLP-1 receptor agonists as cancer-preventive drugs. 1 ; 3
Are GLP-1 Receptor Agonists Linked to Lower Cancer Risk?
A 2025 JAMA Oncology retrospective cohort study using OneFlorida+ electronic health record data followed a target-trial emulation design and compared adults with obesity who used GLP-1 receptor agonists with matched nonusers. The study included 86,632 matched adults: 43,317 GLP-1 receptor agonist users and 43,315 matched nonusers. 1
In that study, the incidence rate of 14 cancers was 13.6 per 1,000 person-years among GLP-1 receptor agonist users compared with 16.4 per 1,000 person-years among nonusers. This translated into a statistically significant lower overall cancer risk, with a hazard ratio of 0.83 and a 95% confidence interval of 0.76 to 0.91. 1
The site-specific findings were particularly relevant for oncology. In that analysis, GLP-1 receptor agonist use was associated with lower risk of endometrial cancer, ovarian cancer, and meningioma. The reported hazard ratios were 0.75 for endometrial cancer, 0.53 for ovarian cancer, and 0.69 for meningioma. 1
These signals are biologically plausible because several of these cancers are linked, directly or indirectly, to obesity, hormonal regulation, inflammation, and metabolic dysfunction. However, biological plausibility is not the same as proof of causality.
The same study also reported a possible kidney cancer signal. The hazard ratio for kidney cancer was 1.38, with a 95% confidence interval of 0.99 to 1.93. 1
This does not definitively establish increased risk, but it shows why the discussion cannot be reduced to a simple “GLP-1 lowers cancer risk” message. For pharma and regulatory teams, such a signal is not proof of harm, but it is a reason for longer follow-up, tumor-specific analysis, and active pharmacovigilance.
Another major study, published in JAMA Network Open in 2024, examined 1,651,452 patients with type 2 diabetes and no prior diagnosis of 13 obesity-associated cancers. 4
In this study, GLP-1 receptor agonists were compared with insulin and metformin. Compared with insulin, GLP-1 receptor agonist use was associated with significantly lower risk for 10 of the 13 obesity-associated cancers studied. 4
The reported hazard ratios versus insulin were 0.35 for gallbladder cancer, 0.37 for meningioma, 0.41 for pancreatic cancer, 0.47 for hepatocellular carcinoma, 0.52 for ovarian cancer, 0.54 for colorectal cancer, 0.59 for multiple myeloma, 0.60 for esophageal cancer, 0.74 for endometrial cancer, and 0.76 for kidney cancer. 4
These findings are notable, but the comparator matters. Because this was an observational comparison, residual confounding remains possible even after propensity-score matching. A lower risk versus insulin may reflect true drug benefit, differences in patient populations, effects of weight loss, differences in diabetes severity, or a combination of these factors.
This is why the metformin comparison is important. In the same JAMA Network Open study, GLP-1 receptor agonists were not associated with a reduced risk of any cancer when compared with metformin. 4
In that same metformin comparison, kidney cancer risk was higher among GLP-1 receptor agonist users, with a hazard ratio of 1.54 and a 95% confidence interval of 1.27 to 1.87. 4
That contrast is one of the most important lessons from the current evidence. The apparent cancer benefit of GLP-1 receptor agonists may depend strongly on the comparison group. It should be interpreted as a prevention signal, not as definitive prevention evidence.
Colorectal Cancer and GLP-1 Receptor Agonists
Colorectal cancer has also attracted specific attention. A JAMA Oncology cohort study of 1,221,218 drug-naive patients with type 2 diabetes found that GLP-1 receptor agonists were associated with lower colorectal cancer risk compared with insulin, with a hazard ratio of 0.56 and a 95% confidence interval of 0.44 to 0.72. 5
GLP-1 receptor agonists were also associated with lower colorectal cancer risk compared with metformin, with a hazard ratio of 0.75 and a 95% confidence interval of 0.58 to 0.97. 5
Among patients with overweight or obesity, the association was stronger versus insulin, with a hazard ratio of 0.50 and a 95% confidence interval of 0.33 to 0.75. 5
Among patients with overweight or obesity, the association also remained significant versus metformin, with a hazard ratio of 0.58 and a 95% confidence interval of 0.38 to 0.89. 5
Still, observational evidence has limits. Cancer development is slow, multifactorial, and affected by screening patterns, lifestyle, comorbidities, medication history, and competing risks. GLP-1 receptor agonist users may differ from nonusers in ways that are not fully measurable in electronic health record datasets. These factors do not invalidate the findings, but they should shape how confidently they are communicated.
Randomized trial evidence is more conservative and should be treated separately from real-world observational data. A 2025 meta-analysis of 50 randomized controlled trials lasting at least 52 weeks found no statistically significant difference in overall cancer risk with GLP-1 receptor agonist treatment compared with control therapies. 3
The Mantel-Haenszel odds ratio for overall cancer was 1.05, with a 95% confidence interval of 0.98 to 1.13. 3
However, the same meta-analysis reported an increased thyroid cancer signal, with a Mantel-Haenszel odds ratio of 1.55 and a 95% confidence interval of 1.05 to 2.27. 3
The same meta-analysis also reported a colorectal cancer signal, with a Mantel-Haenszel odds ratio of 1.27 and a 95% confidence interval of 1.03 to 1.57. 3
This is important for interpretation. The randomized evidence is reassuring for overall cancer risk, but it does not prove cancer prevention. Most diabetes and obesity trials were not designed or powered to detect differences in individual cancer outcomes, and follow-up durations are often too short for cancer incidence endpoints.
Therefore, randomized trial data and observational data currently answer different questions: randomized trials provide stronger safety reassurance for overall risk, while large real-world datasets generate hypotheses about tumor-specific risk reduction or tumor-specific safety signals.
Thyroid Cancer Warnings in GLP-1 Prescribing Information
The clearest regulatory warning in current prescribing information concerns thyroid C-cell tumors. FDA-approved Wegovy prescribing information includes a boxed warning stating that semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors in rodents at clinically relevant exposures. 6
The FDA label also states that it is unknown whether Wegovy causes thyroid C-cell tumors, including medullary thyroid carcinoma, in humans. 6
Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma and in patients with multiple endocrine neoplasia syndrome type 2. 6
This warning is often misunderstood. It is not evidence that GLP-1 receptor agonists cause common thyroid cancers in humans. The FDA label states that human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined. 6
The FDA label also states that postmarketing reports of medullary thyroid carcinoma with liraglutide are insufficient to establish or exclude a causal relationship between medullary thyroid carcinoma and GLP-1 receptor agonist use in humans. 6
For clinicians, patients, and communicators, the distinction matters: the warning should be respected, but it should not be exaggerated into a broad claim that GLP-1 drugs cause thyroid cancer.
Why GLP-1 Drugs Should Not Be Called Cancer-Prevention Drugs Yet
From a pharma perspective, the GLP-1 and cancer story should be approached as an evidence-generation challenge. The opportunity is clear: if sustained metabolic intervention reduces the incidence of obesity-associated cancers, GLP-1 receptor agonists could become relevant to cancer prevention strategy in high-risk populations. But the risk of overclaiming is equally clear. Prevention claims require stronger evidence than observational associations, especially when the intervention may be used by millions of people over long periods.
The most responsible interpretation today is this: current evidence does not show a clear increase in overall cancer risk with GLP-1 receptor agonists. Several large observational studies suggest lower incidence of selected obesity-associated cancers, especially when GLP-1 receptor agonists are compared with insulin. 1 ; 4 ; 5
However, the evidence is not uniform across comparator groups, and randomized trial data do not yet establish a cancer-prevention effect. 4 ; 3
Kidney cancer findings are inconsistent across comparator groups, and thyroid-related concerns remain part of regulatory labeling and ongoing safety interpretation. 1 ; 4 ; 6
The next phase should be more precise. The field needs longer follow-up, cancer registry linkage, tumor-specific endpoints, dose and duration analyses, and better separation of weight-loss-mediated effects from direct drug effects. Studies should also account for screening behavior, diabetes severity, baseline BMI, weight trajectory, metabolic biomarkers, and concomitant medications such as metformin, insulin, and SGLT2 inhibitors.
For now, GLP-1 receptor agonists should not be called cancer-prevention drugs. But they may become part of a broader cancer-prevention conversation because they act on one of the most important modifiable cancer risk pathways: obesity and metabolic dysfunction.
The signal is real enough to study seriously. It is not mature enough to market aggressively. That distinction is where scientific credibility begins.
